Opioid agonist treatment and risk of mortality during opioid overdose public health emergency: population based retrospective cohort study

被引:132
|
作者
Pearce, Lindsay A. [1 ]
Min, Jeong Eun [1 ]
Piske, Micah [1 ]
Zhou, Haoxuan [1 ]
Homayra, Fahmida [1 ]
Slaunwhite, Amanda [2 ]
Irvine, Mike [2 ]
McGowan, Gina [3 ]
Nosyk, Bohdan [1 ,4 ]
机构
[1] British Columbia Ctr Excellence HIV AIDS, Hlth Econ Res Unit, Vancouver, BC V6Z 1Y6, Canada
[2] British Columbia Ctr Dis Control & Prevent, Vancouver, BC V5Z 4R4, Canada
[3] British Columbia Minist Mental Hlth & Addict, Victoria, BC V8W 9P1, Canada
[4] Simon Fraser Univ, Fac Hlth Sci, Burnaby, BC V5A 1S6, Canada
来源
关键词
PHARMACOLOGICAL-TREATMENT; METHADONE; DRUG; BUPRENORPHINE; DEPENDENCE; HEROIN; THERAPY;
D O I
10.1136/bmj.m772
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective - To compare the risk of mortality among people with opioid use disorder on and off opioid agonist treatment (OAT) in a setting with a high prevalence of illicitly manufactured fentanyl and other potent synthetic opioids in the illicit drug supply. Design - Population based retrospective cohort study. Setting - Individual level linkage of five health administrative datasets capturing drug dispensations, hospital admissions, physician billing records, ambulatory care reports, and deaths in British Columbia, Canada. Participants - 55 347 people with opioid use disorder who received OAT between 1 January 1996 and 30 September 2018. Main outcome measures - All cause and cause specific crude mortality rates (per 1000 person years) to determine absolute risk of mortality and all cause age and sex standardised mortality ratios to determine relative risk of mortality compared with the general population. Mortality risk was calculated according to treatment status (on OAT, off OAT), time since starting and stopping treatment (1, 2, 3-4, 5-12, >12 weeks), and medication type (methadone, buprenorphine/naloxone). Adjusted risk ratios compared the relative risk of mortality on and off OAT over time as fentanyl became more prevalent in the illicit drug supply. Results- 7030 (12.7%) of 55 347 OAT recipients died during follow-up. The all cause standardised mortality ratio was substantially lower on OAT (4.6, 95% confidence interval 4.4 to 4.8) than off OAT (9.7, 9.5 to 10.0). In a period of increasing prevalence of fentanyl, the relative risk of mortality off OAT was 2.1 (95% confidence interval 1.8 to 2.4) times higher than on OAT before the introduction of fentanyl, increasing to 3.4 (2.8 to 4.3) at the end of the study period (65% increase in relative risk). Conclusions - Retention on OAT is associated with substantial reductions in the risk of mortality for people with opioid use disorder. The protective effect of OAT on mortality increased as fentanyl and other synthetic opioids became common in the illicit drug supply, whereas the risk of mortality remained high off OAT. As fentanyl becomes more widespread globally, these findings highlight the importance of interventions that improve retention on opioid agonist treatment and prevent recipients from stopping treatment.
引用
收藏
页数:13
相关论文
共 50 条
  • [21] Predicting Mortality Risk After a Hospital or Emergency Department Visit for Nonfatal Opioid Overdose
    Jingchuan Guo
    Wei-Hsuan Lo-Ciganic
    Qingnan Yang
    James L. Huang
    Jeremy C. Weiss
    Gerald Cochran
    Daniel C. Malone
    Courtney C. Kuza
    Adam J. Gordon
    Julie M. Donohue
    Walid F. Gellad
    Journal of General Internal Medicine, 2021, 36 : 908 - 915
  • [22] Somatic health among heroin addicts before and during opioid maintenance treatment: a retrospective cohort study
    Ivar Skeie
    Mette Brekke
    Morten Lindbæk
    Helge Waal
    BMC Public Health, 8
  • [23] Association of medications for opioid use disorder with reduced risk of repeat opioid overdose in Medicaid: A cohort study
    Tipping, Andrew D.
    Nowels, Molly
    Moore, Clara
    Samples, Hillary
    Crystal, Stephen
    Olfson, Mark
    Williams, Arthur Robinson
    -Woodruff, Jodi Heaps
    JOURNAL OF SUBSTANCE USE & ADDICTION TREATMENT, 2024, 157
  • [24] Somatic health among heroin addicts before and during opioid maintenance treatment:: a retrospective cohort study
    Skeie, Ivar
    Brekke, Mette
    Lindbaek, Morten
    Waal, Helge
    BMC PUBLIC HEALTH, 2008, 8 (1)
  • [25] Opioid Agonist Therapy During Hospitalization Within the Veterans Health Administration: a Pragmatic Retrospective Cohort Analysis
    Kelsey C. Priest
    Travis I. Lovejoy
    Honora Englander
    Sarah Shull
    Dennis McCarty
    Journal of General Internal Medicine, 2020, 35 : 2365 - 2374
  • [26] Opioid Agonist Therapy During Hospitalization Within the Veterans Health Administration: a Pragmatic Retrospective Cohort Analysis
    Priest, Kelsey C.
    Lovejoy, Travis I.
    Englander, Honora
    Shull, Sarah
    McCarty, Dennis
    JOURNAL OF GENERAL INTERNAL MEDICINE, 2020, 35 (08) : 2365 - 2374
  • [27] Cohort Study of the Impact of High-Dose Opioid Analgesics on Overdose Mortality
    Dasgupta, Nabarun
    Funk, Michele Jonsson
    Proescholdbell, Scott
    Hirsch, Annie
    Ribisl, Kurt M.
    Marshall, Steve
    PAIN MEDICINE, 2016, 17 (01) : 85 - 98
  • [28] Risk of Opioid Overdose Associated With Concomitant Use of Opioids and Skeletal Muscle Relaxants: A Population-Based Cohort Study
    Li, Yan
    Delcher, Chris
    Wei, Yu-Jung Jenny
    Reisfield, Gary M.
    Brown, Joshua D.
    Tighe, Patrick
    Winterstein, Almut G.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2020, 108 (01) : 81 - 89
  • [29] Opioid Use During Pregnancy: A Population-Based Cohort Study
    Falk, Jamie
    Dahl, Matt
    Raymond, Colette
    Chateau, Dan
    Katz, Alan
    Leong, Christine
    Burland, Elaine
    Bugden, Shawn C.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2016, 25 : 331 - 331
  • [30] Sex Differences in Dose Escalation and Overdose Death during Chronic Opioid Therapy: A Population-Based Cohort Study
    Kaplovitch, Eric
    Gomes, Tara
    Camacho, Ximena
    Dhalla, Irfan A.
    Mamdani, Muhammad M.
    Juurlink, David N.
    PLOS ONE, 2015, 10 (08):